Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.75 mg or about 1.5 mg albuterol sulfate.
1 . A system for providing relief of bronchospasm in an individual 2 to 12 years suffering from obstructive airway disease, said system comprising:
(a) at least one single dispensing container; said container prefilled with about 0.1 ml to about 1.0 ml of a premixed, premeasured, aqueous inhalation solution comprising a single unit dose of a therapeutically effective amount of albuterol; wherein said amount of albuterol ranges from about 0.63 mg to about 1.5 mg; the solution being suitable for nebulization.
2 . The system of claim 1 , wherein the container is prefilled with about 0.05 ml to about 0.8 ml of the inhalation solution.
3 . The system of claim 1 , wherein one container is prefilled with about 0.1 ml to about 0.5 ml of the inhalation solution.
4 . The system of claim 1 , wherein the container is prefilled with about 0.25 ml or about 0.5 ml of the inhalation solution.
5 . The system of claim 1 , wherein the amount of albuterol is about 0.63 mg or about 1.25 mg.
6 . The system of claim 1 , wherein the container is prefixed with about 0.5 mml of the inhalation solution, and the amount of albuterol is about 0.63 mg or 1.25 mg.
7 . The system of claim 1 , wherein the inhalation solution in each of the one or more containers is sterile.
8 . The system of claim 1 , wherein the inhalation solution in each of the one or more containers is free of benzalkonium chloride.
9 . The system of claim 1 , wherein the system further comprises a label which indicates that the inhalation solution can be used to relieve broncospasm in individuals 2 to 12 years of obstructive airway disease.
10 . The system of claim 9 , wherein said label comprises instructions for using the solution to relieve said bronchospasm.
11 . The system of claim 9 , wherein said label providing prescribing information comprising efficacy, dosage, administration, contraindication and adverse reaction information pertaining to the inhalation solution in the container.
12 . A system for reducing medication error, reducing nebulizer treatment time and enhancing therapeutic compliance of an individual 2 to 12 years of obstructive airway disease, the prepackaged therapeutic system comprising:
(a) one or more dispensing containers; the one or more containers each prefilled with about 0.1 ml to about 1.0 ml of a sterile, benzlakonium chloride-free, premixed, premeasured aqueous inhalation solution comprising a unit dose of a therapeutically effective amount of albuterol; wherein the amount of albuterol is about 0.63 mg or 1.25 mg; the inhalation solution in each of the one ore more containers is suitable for nebulization in a nebulizer; the inhalation solution in each of the one or more containers is stable.
13 . A method of inducing bronchodialation or providing relief of bronchospasm in an individual 2 to 12 years suffering from obstructive airway disease, said method comprising the step of:
(a) administrating to the individual at least one single dispensing containers; the one or more containers each prefilled with about 0.1 ml to about 1.0 ml of a premixed, premeasured aqueous inhalation solution comprising a unit dose of a therapeutically effective amount of albuterol; wherein the amount of albuterol is about 0.6 mg to about 1.5 mg; the inhalation solution in each of the one or more containers is suitable for nebulization in a nebulizer.
14 . The method of claim 13 , wherein each of the one ore more containers is prefilled with about 0.1 ml to about 0.8 ml of the inhalation solution.
15 . The method of claim 13 , wherein each of the one or more containers is prefilled with about 0.1 ml to about 0.5 ml of the inhalation solution.
16 . The method of claim 13 , wherein each of the one or more containers is prefilled with about 0.25 ml or 0.5 ml of the inhalation solution.
17 . The method of claim 13 , further comprising the step of providing dosage, administration, contraindication and adverse reaction data pertaining to the inhalation solution in each of the one ore more containers.
18 . The method of claim 13 , wherein the albuterol is albuterol base.
19 . A method of inducing bronchodialation or providing relief of bronchospasm, reducing medication error, reducing nebulization treatment time and enhancing therapeutic compliance of an individual 2 to 12 years suffering from obstructive airway disease, said method comprising the steps:
(a) placing the inhalation solution of claim 1 into a chamber of a nebulizer, said nebulizer having a mouthpiece or facemask associated with the chamber of the nebulizer;
(b) positioning the mouthpiece or facemask in close proximity to the individual's mouth or face;
(c) passing the inhalation solution in a mist form from the nebulizer chamber through the mouthpiece or facemask to the individual while the individual breathes into the mouthpiece or facemask; and
(d) the individual breathing into the mouthpiece or facemask until the nebulization treatment is finished.
20 . The method of claim 19 , wherein the nebulization treatment is finished when at least substantially all the mist is removed from the nebulizer chamber.
21 . The method of claim 19 , wherein at least substantially all the mist is removed from the nebulizer chamber in less than 12 minutes.
22 . The method of claim 19 , wherein at substantially all the mist is removed from the nebulizer chamber in less than 10 minutes.
23 . The method of claim 19 , wherein at least substantially all the mist is removed from the nebulizer chamber in less than 8 minutes.
24 . The method of claim 19 , wherein at least substantially all the mist is removed from the nebulizer chamber in less than 6 minutes.
25 . The method of claim 19 , wherein at least substantially all the mist is removed from the nebulizer chamber in less than 4 minutes.
26 . A method of reducing medication error and enhancing therapeutic compliance in an individual 2 to 12 years suffering from obstructive airway disease, said method comprising the steps of:
(a) administering to the individual at least one single dispensing container wherein the container is prefilled with about 0.1 ml to about 0.5 ml of a sterile, benzalkonium chloride-free, premixed, premeasured aqueous inhalation solution comprising a unit dose of a therapeutically effective amount of albuterol; wherein the amount of albuterol ranges from about 0.60 to 1.30 mg; the inhalation solution in the container is suitable for nebulization in a nebulizer; the inhalation solution in the container is stable, in that the inhalation solution is therapeutically effective following storage for 12 months at 25° C.; and
(b) providing dosage information pertaining to the inhalation solution in the container; and
(c) providing administration, information, wherein said administration information comprises instructions for the use of the unit dose of albuterol to treat pediatric asthma.
27 . The method of claim 26 , wherein the dispensing container is prefilled with 0.25 ml or 0.5 ml.